DPYSL5 and small cell lung carcinoma: For example, in a study of 200 SCLC patients, the prevalence rates of onconeural antibodies for Hu, CRMP5, amphiphysin, Ri, Ma2, and Yo were 22.5%, 0.5%, 2.5%, 1.5%, 1%, and 0.5%, respectively [11].